AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics, Inc. (“Mati”) announced that its international patent portfolio now comprises 100 issued patents. Included in the portfolio is recently granted U.S. Patent No. 9,610,271 titled, “Sustained release delivery of active agents to treat glaucoma and ocular hypertension." The patent, which expires in 2033, contains subject matter related to a method for decreasing ocular pressure by implanting a lacrimal implant into one or both puncta (tear ducts) of the eye.
This newly issued patent further enhances Mati’s patent portfolio, which consists of 100 issued patents and numerous patent applications to which Mati has exclusive rights in the U.S. and other major international markets. The patents cover 17 patent families, including important elements of Mati's Evolute® punctal plug delivery system for treatment of ocular indications. The Evolute® platform includes features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution and sustained release formulations currently in development for the treatment of post-operative pain and inflammation. The proprietary technology has the potential to be used for multiple disease states with consistent, sustained efficacy.
“The granting of 100 patents is a significant milestone for any company, but a very meaningful milestone for a small private company such as Mati. Our unique platform technology is under development for a number of indications including post-operative inflammation and pain, glaucoma and ocular hypertension, ocular allergy, and dry eye,” said Bob Butchofsky, CEO of Mati. “Since its inception over four years ago, Mati has focused on innovation, and continues to build a significant intellectual property portfolio for sustained drug delivery platform covering the U.S., Europe, Canada, Japan, and China. We believe our patent portfolio provides Mati with a competitive advantage in research and development that will remain in place for many years to come.”
About Mati Therapeutics, Inc.
Mati is developing the Evolute® sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is easily inserted into a patient’s punctum. The device has already been approved to treat dry eye syndrome, but Mati is the first to conduct clinical trials in the U.S., using punctal plugs as an anchoring device for a drug delivery platform. A drug-eluting core is inserted into Mati’s proprietary punctal plug, which allows medication to be continuously released into the tear film of the eye over a period of time. Mati believes the Evolute® platform has the potential to become a more reliable alternative to several eye drop therapies, which can be ineffective because many patients are unwilling or unable to adhere to self-administered eye-drop regimens.
Mati has completed multiple Phase II clinical trials using the Evolute® platform, including multiple trials in glaucoma, ocular hypertension, and allergy patients. Mati’s proprietary punctal plug design has demonstrated excellent lower punctum retention rates of 92% and 96% over a 12-week follow-up period in two separate multi-center U.S. clinical trials.
To learn more about Mati Therapeutics, visit www.MatiTherapeutics.com.
